You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微芯生物(688321.SH):西格列他鈉片於今年3月進入國家醫保目錄,市場需求快速增長
格隆匯 09-05 18:36

格隆匯9月5日丨微芯生物(688321.SH)接受特定對象調研時表示,公司已有兩款原創新藥在中國獲批上市,同時公司也積極響應並推動藥物進入國家醫保目錄,提高患者的可及性。西達本胺片外周T細胞淋巴瘤適應症於2017年首次進入國家醫保目錄並已經歷了兩次談判續約,目前銷售收入穩定增長;西格列他鈉片於今年3月進入國家醫保目錄,市場需求快速增長;公司今年也提交了西達本胺片乳腺癌適應症加入2023年國家醫保目錄的申請。

其進一步表示,公司西達本胺的毛利率水平基本維持在95%左右,公司已建立了完整、成本可控的生產及質量體系,西達本胺的成本控制和毛利率水平是比較穩定的。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account